At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 363 enrolled
Drug / intervention
Calcipotriene Foam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam In The Treatment Of Moderate Plaque-Type Scalp And Body Psoriasis
In Brief
A Phase 3 clinical trial evaluating Calcipotriene Foam and Vehicle Foam for Psoriasis. Completed, enrolled 363 participants across 26 sites.
Detailed Summary
The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedJun 8, 2010
Enrollment StartMay 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.1 years ago
Interventions
Calcipotriene Foamdrug
Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
Vehicle Foamdrug
Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group